How to transfer my Strattera prescription to Pennsylvania

If you’re navigating ADHD treatment in 2025, you’ve likely wondered: Can I get ADHD medication through telehealth? The short answer is yes—especially for non-stimulant medications like Strattera (atomoxetine). But the rules vary by state, medication type, and provider credentials. This guide breaks down everything you need to know about accessing ADHD non-stimulant medications online, including current regulations, state-specific requirements, and what to expect from a telehealth evaluation.

Understanding ADHD Non-Stimulant Medications

What Are Non-Stimulant ADHD Medications?

Non-stimulant medications treat ADHD through different mechanisms than stimulants like Adderall or Ritalin. The most common non-stimulant is Strattera (atomoxetine), which works by increasing norepinephrine levels in the brain. Crucially, Strattera is not a controlled substance—a designation that fundamentally changes how it can be prescribed via telehealth.

Other non-stimulant options include:

• Strattera (atomoxetine) – The only FDA-approved non-stimulant specifically for ADHD
• Intuniv (guanfacine) – Originally a blood pressure medication, now used for ADHD
• Kapvay (clonidine) – Another blood pressure drug repurposed for ADHD symptoms
• Qelbree (viloxazine) – A newer non-stimulant approved in 2021

Why Choose Non-Stimulants?

Non-stimulant medications may be preferred if you:

• Have a history of substance abuse concerns
• Experience problematic side effects from stimulants
• Have certain heart conditions that make stimulants risky
• Prefer medication without abuse potential
• Need all-day symptom coverage without multiple doses
• Live in a state with stricter stimulant prescribing rules

While non-stimulants typically take 4-6 weeks to reach full effectiveness (compared to stimulants’ same-day impact), they offer steady symptom management and carry no risk of dependency.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Telehealth Advantage for Non-Stimulants

Federal Regulations: The Key Difference

Here’s the critical distinction: Non-stimulant ADHD medications face virtually no federal telehealth restrictions. Unlike controlled substances (Schedule II-V drugs like Adderall or Vyvanse), Strattera isn’t subject to the Ryan Haight Act’s in-person examination requirement.

The Drug Enforcement Administration (DEA) has extended pandemic-era telehealth flexibilities for controlled substances through December 31, 2025, allowing stimulant prescriptions via telehealth without a prior in-person visit. However, these temporary rules don’t affect non-stimulants—because non-stimulants were never restricted in the first place.

This means Strattera and similar medications can be prescribed through telehealth under standard medical practice guidelines, regardless of what happens with DEA rule extensions. Your provider simply needs to:

• Be licensed in your state
• Conduct a proper evaluation via secure video
• Follow standard diagnostic criteria for ADHD
• Document the patient-provider relationship appropriately

State-by-State Telehealth Landscape

While federal law is permissive for non-stimulants, state regulations still matter. Here’s what you need to know about major states:

California

California embraces telehealth for mental health treatment. No in-person exam is required for prescribing non-controlled medications like Strattera. Providers must conduct a ‘good faith examination,’ which can be satisfied through comprehensive video consultation. Nurse practitioners in California have independent practice authority after meeting experience requirements (AB 890), meaning they can evaluate and prescribe ADHD medications without physician oversight.

New York

New York reinstated strict in-person requirements in 2025—but only for controlled substances. The state’s May 2025 Final Rule requires an initial in-person evaluation before prescribing any Schedule II-IV drug via telehealth. This doesn’t affect Strattera prescriptions, which can be initiated entirely through telehealth. New York allows nurse practitioners to practice independently after completing 3,600 supervised hours.

Florida

Florida permits telehealth ADHD treatment with some nuances. The state requires video visits (no phone-only consultations) for prescribing any medication for mental health conditions. Florida’s controlled substance rules are complex—Schedule II stimulants can’t be prescribed via telehealth unless treating a ‘psychiatric disorder’ (which includes ADHD). For Strattera, there are no special restrictions beyond standard telehealth protocols.

Texas

Texas is remarkably telehealth-friendly for behavioral health services. No in-person visit is required for ADHD treatment via telemedicine. However, Texas has stricter rules for nurse practitioners and physician assistants: they cannot prescribe Schedule II medications (stimulants) in regular outpatient settings, only in hospitals or hospice care. This doesn’t affect Strattera prescribing by NPs/PAs, which is allowed under collaborative agreements.

Alabama

Alabama maintains one of the strictest telehealth frameworks. After four telehealth visits for the same condition, patients must have an in-person evaluation within 12 months—unless the treatment is classified as mental health services, which are exempt from this requirement. Alabama also has unique requirements for controlled substance prescribing via telehealth, but again, these don’t impact non-stimulant medications.

New Hampshire

New Hampshire recently modernized its telehealth laws. Effective August 2025, Senate Bill 252 removed the previous in-person examination requirement for controlled substances, replacing it with a requirement for at least annual follow-up evaluations (which can be conducted via telehealth). For non-controlled medications, there are no special restrictions. New Hampshire allows nurse practitioners full independent practice and prescribing authority.

What to Expect: The Telehealth Evaluation Process

Comprehensive Assessment Is Required

Legitimate telehealth ADHD providers cannot simply hand out prescriptions after a quick chat. Expect a thorough evaluation that mirrors in-person diagnostic standards:

Initial Consultation (45-60 minutes typically)

• Detailed symptom history using DSM-5 criteria
• Assessment of symptoms across multiple settings (work, school, home, relationships)
• Childhood onset verification (ADHD symptoms must be present before age 12)
• Medical history review, including heart conditions, blood pressure, liver function
• Mental health screening for anxiety, depression, bipolar disorder
• Substance use history
• Current medications and supplements
• Family history of ADHD and other conditions

Diagnostic ToolsYour provider may use:

• Standardized rating scales (ASRS-v1.1, Conners Adult ADHD Rating Scale)
• Structured clinical interviews
• Collateral information from family members or partners
• Review of past medical records, school records, or previous diagnoses
• Cognitive or attention testing (some platforms offer computerized assessments)

Documentation RequirementsBe prepared to provide:

• Government-issued photo ID (required for DEA compliance)
• Insurance information or payment details
• Previous medical records if available
• Contact information for your primary care provider
• Emergency contact information

Who Can Prescribe ADHD Medications via Telehealth?

Physicians (MD/DO)Licensed physicians can prescribe all ADHD medications—stimulant and non-stimulant—via telehealth in every state, as long as they hold a valid medical license in your state and have DEA registration (if prescribing controlled substances).

Nurse Practitioners (NP)NP prescribing authority varies significantly by state:

• Independent practice states (California, New York, New Hampshire, Illinois, and 20+ others): NPs can diagnose ADHD and prescribe all medications, including controlled substances, without physician oversight after meeting experience requirements
• Collaborative practice states (Florida, Texas, Pennsylvania, Georgia): NPs must have a physician collaborative agreement but can still prescribe non-stimulants freely; stimulant prescribing depends on state-specific protocols
• Restricted states (Georgia, Missouri): NPs face limitations on Schedule II (stimulant) prescribing, though non-stimulants like Strattera remain accessible

Physician Assistants (PA)PAs typically practice under physician supervision across all states. Most can prescribe non-stimulant ADHD medications with appropriate delegation agreements. Schedule II prescribing by PAs varies—some states allow it with restrictions (30-day supply limits, certain practice settings only).

Important: Klarity Health connects you with licensed providers in your state who have the appropriate credentials and DEA registration to prescribe ADHD medications. You’ll be matched with a psychiatrist, psychiatric nurse practitioner, or other qualified mental health prescriber based on your location and needs.

Medication Management and Safety Considerations

Strattera-Specific Information

If your provider recommends Strattera, here’s what you should know:

How It WorksStrattera is a selective norepinephrine reuptake inhibitor (SNRI). Unlike stimulants that work within hours, Strattera requires consistent daily use for 4-6 weeks to achieve full therapeutic effect. This ‘delayed onset’ is actually an advantage for some patients—it provides steady symptom control without the ups and downs some people experience with stimulant medications.

Dosing and Supply

• Starting dose typically 40mg daily, may be increased to 80-100mg
• Can be prescribed in 90-day supplies (unlike stimulants which require monthly prescriptions)
• Refills are allowed on a single prescription
• No special pharmacy restrictions
• Can be split into twice-daily dosing if side effects occur

Side Effects to MonitorCommon side effects include:

• Decreased appetite (usually mild compared to stimulants)
• Upset stomach, nausea (often improves after first 1-2 weeks)
• Fatigue or drowsiness (taking at bedtime may help)
• Dizziness when standing (especially when starting)
• Dry mouth
• Sleep disturbances

Serious (but rare) risks include:

• Increased suicidal thoughts in children/adolescents (FDA black box warning)
• Liver damage (very rare; monitored through follow-up labs if symptoms appear)
• Severe allergic reactions
• Heart rate and blood pressure changes

ContraindicationsYou cannot take Strattera if you:

• Have narrow-angle glaucoma
• Have taken an MAOI antidepressant in the past 14 days
• Have a proven severe allergic reaction to atomoxetine

Caution required if you have:

• Heart problems or high blood pressure
• History of bipolar disorder (may trigger manic episodes)
• Liver problems
• History of suicidal thoughts
• Seizure disorders

Telehealth Follow-Up Protocol

Responsible telehealth ADHD treatment includes regular monitoring:

First Month

• Follow-up at 2 weeks to assess initial response and side effects
• Dose adjustment if needed
• Blood pressure check (can be done at local pharmacy or with home monitor)
• Safety assessment, especially for mood changes

Ongoing Care

• Monthly or quarterly check-ins depending on stability
• Symptom rating scales to track improvement
• Side effect monitoring
• Medication adherence discussion
• Integration with therapy or coaching

Your telehealth provider should also:

• Coordinate with your primary care physician (with your permission)
• Review medication history through prescription monitoring databases
• Provide clear instructions for emergency situations
• Offer resources for non-medication ADHD management strategies

Red Flags and Patient Safety

Identifying Legitimate vs. Questionable Services

The ADHD telehealth space has faced scrutiny following investigations into companies like Cerebral and Done in 2022-2023. To protect yourself:

Green Flags (What to Look For):

• Requires comprehensive video evaluation before prescribing
• Uses licensed, credentialed providers (you can verify)
• Discusses both medication and non-medication treatments
• Conducts thorough diagnostic assessment using DSM-5 criteria
• Explains risks, benefits, and alternatives
• Schedules regular follow-ups
• Requires informed consent documentation
• Integrates or refers to therapy services
• Has clear privacy and security protocols (HIPAA-compliant)
• Accepts insurance or offers transparent pricing

Red Flags (Warning Signs):

• Guarantees prescription before evaluation
• Offers prescriptions after brief text-based questionnaire
• No video visit required
• Can’t verify provider credentials
• Pushes for higher doses or early refills
• No discussion of side effects or monitoring
• Avoids requesting medical history
• Operates from overseas or unclear jurisdiction
• Extremely low prices or ‘too good to be true’ claims
• No established patient portal or medical records access

Patient Eligibility Considerations

You may NOT be a candidate for telehealth ADHD medication if you have:

• Active uncontrolled substance use disorder
• Severe, unstable mental health conditions (acute psychosis, uncontrolled bipolar disorder)
• Recent hospitalization for psychiatric crisis
• Serious cardiovascular conditions requiring specialist monitoring
• Complex medication regimens needing in-person management
• Age under the platform’s minimum (many require 18+ for controlled substances)

These situations don’t mean you can’t get treatment—they mean in-person evaluation is necessary first to ensure safety. Once stabilized, you may transition to telehealth for ongoing management.

Practical Considerations and Cost

Insurance Coverage

Most health insurance plans now cover telehealth mental health services at parity with in-person visits, thanks to pandemic-era policy changes that many states made permanent. This includes:

• Evaluation and diagnosis visits
• Medication management appointments
• Follow-up consultations

Check your coverage for:

• Copay amounts for telehealth psychiatry
• Whether your plan covers out-of-state telehealth providers (if using a multi-state platform)
• Prior authorization requirements for specific medications
• Prescription coverage and tier placement for Strattera (usually Tier 2-3, generic available)

Klarity Health accepts both insurance and cash pay, offering transparent pricing so you know costs upfront. For patients without insurance or with high deductibles, cash pay options often provide predictable, affordable rates for both evaluations and follow-up visits.

Pharmacy and Prescription Fulfillment

For Non-Stimulants Like Strattera:

• Electronic prescriptions sent directly to your chosen pharmacy
• Most pharmacies fill telehealth prescriptions without issue
• Can use mail-order pharmacies for 90-day supplies (often cheaper with insurance)
• Generic atomoxetine widely available (significantly less expensive than brand-name)
• No special DEA paperwork or ‘red C’ tracking required
• Refills can be called in or e-prescribed without a new evaluation

Tips for Smooth Pharmacy Experience:

• Establish relationship with one primary pharmacy
• Provide your pharmacy information during initial telehealth visit
• Check that your pharmacy is in-network if using insurance
• Ask about 90-day supply pricing (often better value)
• Have your provider send prescriptions with appropriate refills
• Inform the pharmacy if you’re new to their system from a telehealth provider

Time and Convenience Factors

Average Timeline:

• Initial appointment booking: Often available within 24-48 hours (some platforms offer same-day)
• Evaluation appointment: 45-60 minutes via video
• Prescription sent: Immediately after evaluation if appropriate (available at pharmacy within hours)
• Start medication: Same day or next day typically
• Follow-up scheduled: Usually 2 weeks after starting

Compared to traditional in-person:

• No driving to appointments or sitting in waiting rooms
• Flexible scheduling (early morning, evening, weekend slots often available)
• Less time off work or away from caregiving responsibilities
• Continuation of care if you move to a new location (with some limitations by state licensing)

The Future of Telehealth ADHD Treatment

Regulatory Landscape 2025-2026

Current Status (as of December 2025):The DEA’s third temporary extension of COVID-era telehealth flexibilities for controlled substances expires December 31, 2025. A fourth extension for 2026 is under review, but uncertainty remains about long-term policy.

What This Means for Non-Stimulants:Essentially nothing. Since Strattera and other non-stimulants aren’t DEA-controlled, they’re unaffected by these rule changes. You can continue accessing non-stimulant ADHD medications via telehealth regardless of what happens with controlled substance regulations.

What This Means for Stimulants:If you’re taking or considering stimulant medications, stay informed. Potential scenarios for 2026:

• Another extension (most likely based on OMB review status)
• New permanent telehealth prescribing framework with additional requirements
• Return to pre-pandemic rules requiring in-person exam (least likely given political and practical realities)

State-Level Trends:More states are modernizing telehealth laws:

• Expanding permanent telehealth access
• Reducing or eliminating in-person requirements for mental health treatment
• Improving interstate licensing reciprocity
• Strengthening prescription monitoring programs
• Enhancing patient privacy protections

Proposed Federal Changes

Several bills under consideration could reshape telehealth ADHD treatment:

• TREATS Act: Would allow easier tele-psychiatry and cross-state prescribing
• DEA Special Registration Rule: Proposed permanent telehealth prescribing pathway with additional safeguards (still pending)
• Medicare telehealth expansion: Could influence private insurance policies

Making the Most of Telehealth ADHD Treatment

Before Your First Appointment

Prepare These Materials:

1. Symptom journal noting ADHD impacts across different settings
2. List of current and past medications (names, doses, duration)
3. Any previous ADHD evaluations, testing results, or diagnoses
4. School records showing childhood academic/behavioral challenges (if available)
5. List of questions about treatment options

Set Up Your Space:

• Quiet, private location where you can speak openly
• Good lighting and stable internet connection
• Device with working camera and microphone
• Charger or fully charged device
• Notepad for taking notes during the visit

During Your Evaluation

Be Honest and Thorough:Your provider needs complete information to help you safely. This includes:

• Substance use history (past and present)
• Mental health challenges beyond ADHD
• Medications you’ve tried and why they didn’t work
• Real-world impact of symptoms on your life
• Treatment goals and concerns

Don’t be afraid to:

• Ask questions about different medication options
• Express preferences (e.g., ‘I’d prefer to try a non-stimulant first’)
• Discuss concerns about side effects
• Request information in writing
• Take time to think about starting medication

Building a Successful Treatment Plan

Medication is just one component of comprehensive ADHD management:

Combine Medication With:

• Cognitive behavioral therapy (CBT) for ADHD
• Executive function coaching
• Organizational systems and tools
• Sleep hygiene improvements
• Exercise routine (proven to help ADHD symptoms)
• Nutrition optimization
• Stress management techniques
• Workplace or academic accommodations

Track Your Progress:

• Keep a symptom log noting improvements and challenges
• Monitor side effects (severity, duration, impact)
• Note medication timing and any dose changes
• Track sleep, appetite, mood, energy levels
• Document work/school performance changes

Communicate Regularly:Don’t wait for scheduled follow-ups if you experience:

• Severe or concerning side effects
• Suicidal thoughts or severe mood changes
• Worsening ADHD symptoms
• Questions about dosing or medication changes
• Problems with pharmacy or prescription issues

Why Choose Klarity Health for Telehealth ADHD Treatment

Klarity Health offers a patient-centered approach to ADHD care that addresses common barriers to treatment:

Provider AvailabilitySkip the months-long wait lists typical of traditional psychiatry. Klarity connects you with licensed providers who often have appointments available within days, not months. Our network includes psychiatrists and psychiatric nurse practitioners experienced in ADHD diagnosis and treatment across the lifespan.

Transparent PricingKnow what you’ll pay before booking. Whether you’re using insurance or paying cash, Klarity provides clear cost information upfront—no surprise bills or hidden fees. We accept both insurance and self-pay to accommodate different patient needs and financial situations.

Comprehensive CareOur providers take time for thorough evaluations and ongoing management. You’re not rushed through a 15-minute appointment. Initial evaluations are comprehensive, and follow-up visits provide adequate time to discuss how treatment is working and make adjustments as needed.

State-Licensed ProvidersAll Klarity providers are licensed in the states where they practice and credentialed to prescribe ADHD medications. We handle the complexity of varying state regulations so you can focus on your treatment.

Flexible Treatment OptionsWhether you need stimulant or non-stimulant medication, therapy, or a combination, Klarity providers work with you to develop an individualized treatment plan. We understand that ADHD treatment isn’t one-size-fits-all.

Common Questions About Online ADHD Non-Stimulant Prescriptions

Q: Can I get Strattera prescribed on my first telehealth visit?A: Potentially, yes. If you complete a comprehensive evaluation and your provider determines Strattera is appropriate for your symptoms and medical history, they can prescribe it during your initial visit. The prescription will be sent electronically to your pharmacy, typically available for pickup within hours.

Q: Do I need an in-person follow-up after starting medication via telehealth?A: For non-stimulant medications, most states don’t require in-person visits. Your follow-up appointments can continue via telehealth as long as you’re stable and responding well to treatment. Some states (like Alabama) have 12-month in-person requirements for long-term telehealth care, though mental health services are often exempt.

Q: Will my regular doctor know I’m getting ADHD treatment via telehealth?A: Only if you provide consent for your Klarity provider to communicate with them—which we encourage. Coordination with your primary care doctor ensures comprehensive care, helps avoid medication interactions, and provides continuity if you have other health conditions. Your privacy is protected by HIPAA regulations.

Q: What if Strattera doesn’t work for me?A: Your provider will work with you to adjust the dose, try a different non-stimulant, or potentially transition to a stimulant medication if appropriate. Treatment optimization often requires trying multiple approaches. This process is collaborative, and your input about how you’re responding is essential.

Q: Can I use telehealth for ADHD treatment if I’m traveling or living abroad temporarily?A: Telehealth providers must be licensed in the state where you’re physically located during the appointment. If you’re temporarily in another U.S. state, check whether your provider is licensed there. International prescribing isn’t typically allowed—you’d need to establish care with a local provider.

Q: Are there age restrictions for telehealth ADHD treatment?A: This varies by platform. Many telehealth services focus on adults (18+) for controlled substance prescribing, though some treat adolescents with parental consent. Strattera is FDA-approved for ages 6 and older, but telehealth providers may have minimum age policies. For young children, in-person evaluation is usually recommended.

Taking the Next Step

If you’re struggling with ADHD symptoms—difficulty concentrating, disorganization, restlessness, impulsivity—you don’t have to wait months for an appointment or worry about the stigma of seeking treatment. Non-stimulant medications like Strattera offer an accessible, non-controlled option that can be prescribed safely and legally through telehealth in all 50 states.

The process is straightforward:

1. Book a comprehensive evaluation with a licensed provider
2. Complete thorough assessment including symptom history and medical screening
3. Discuss treatment options including non-stimulant medications
4. Receive prescription (if appropriate) sent directly to your pharmacy
5. Schedule follow-up to monitor response and adjust treatment as needed

Living with untreated ADHD affects every area of life—work performance, relationships, self-esteem, and daily functioning. But effective treatment is more accessible than ever through secure, high-quality telehealth services.

Ready to get started? Klarity Health can connect you with an experienced provider who understands ADHD and can help you determine whether medication, therapy, or a combination approach is right for you. With flexible scheduling, transparent pricing, and both insurance and cash pay options, quality ADHD care fits into your life and budget.

Don’t let accessibility barriers keep you from the treatment you deserve. Book your evaluation today and take the first step toward better symptom management and improved quality of life.

Citations & Sources

1. DEA ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescribing Controlled Substances’ (November 2024) – FierceHealthcare. Confirms extension of telehealth prescribing rules through December 31, 2025. www.fiercehealthcare.com

2. ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions’ – Sheppard Mullin Healthcare Law Blog (August 15, 2025). Comprehensive 50-state analysis of telehealth laws including Florida, New Hampshire, Texas requirements. www.sheppardhealthlaw.com

3. ‘The Telehealth Compliance Trap: How Alabama, New York, and California Are Quietly Rewriting the Rules’ – RxAgent.co (October 2025). Details state-specific restrictions and enforcement trends in telehealth prescribing. www.rxagent.co

4. ‘Is Strattera a controlled substance?’ – Medical News Today (January 14, 2025). Medical review confirming Strattera’s non-controlled status and prescribing flexibility. www.medicalnewstoday.com

5. ‘Can an NP Prescribe Schedule 2 in Texas?’ – SingleAimHealth (December 9, 2025). Analysis of Texas nurse practitioner prescribing authority and limitations for controlled substances. www.singleaimhealth.com

Note: This article was verified current as of December 17, 2025. Telehealth regulations continue to evolve. Always confirm current requirements with your provider and state medical board.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment